Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differentiating agents and nontoxic therapies.

C E Myers1

  • 1Department of Medicine, University of Virginia School of Medicine, Charlottesville, USA.

The Urologic Clinics of North America
|June 11, 1999
PubMed
Summary

New anticancer drugs target genetic changes driving cancer. Suramin blocks malignant transformation loops, while fatty acids and other agents like vitamin D show promise for cancer therapy with low toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overview of the early campaign diagnostics for the SPARC tokamak (invited).

The Review of scientific instruments·2024
Same author

Development of the neutral gas diagnostic system for neutral pressure measurements and gas analysis on the SPARC tokamak.

The Review of scientific instruments·2024
Same author

Development of a thermal diagnostic system for the SPARC tokamak.

The Review of scientific instruments·2024
Same author

Development of a bolometry diagnostic for SPARC.

The Review of scientific instruments·2024
Same author

Plasmoid Formation and Strong Radiative Cooling in a Driven Magnetic Reconnection Experiment.

Physical review letters·2024
Same author

AC compensation of 3D magnetic diagnostic signals in DIII-D and National Spherical Torus Experiment-Upgrade (NSTX-U) for real-time application.

The Review of scientific instruments·2022

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Understanding oncogenes and genetic mutations driving malignant transformation opens new avenues for cancer drug development.
  • Autocrine loops are critical mechanisms in malignant transformation, presenting a target for therapeutic intervention.

Purpose of the Study:

  • To review novel anticancer agents and their mechanisms of action, focusing on those targeting genetic alterations and cellular processes.
  • To highlight drugs like Suramin that block autocrine loops and other agents with potential for low-toxicity cancer treatment.

Main Methods:

  • Review of scientific literature on oncogenes, malignant transformation, and emerging anticancer agents.
  • Analysis of drug mechanisms, including Suramin's blockade of autocrine loops and the role of fatty acids.

Main Results:

  • Suramin is identified as the first drug to inhibit malignant transformation by blocking autocrine loops.
  • Phenylacetate and related compounds induce differentiation in normal and malignant cells.
  • Arachidonic acid influences prostate cancer progression, with its effects modifiable by diet and pharmacology.

Conclusions:

  • Targeting oncogenic pathways and cellular differentiation offers promising strategies for cancer therapy.
  • A range of agents, including Suramin, fatty acids, vitamin D analogs, isoflavones, green tea polyphenols, and retinoic acid analogs, show potential for effective and low-toxicity cancer treatment.

Related Experiment Videos